ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health Care • China
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullish•Quantitative Analysis
•05 Sep 2025 10:20

Hong Kong Buybacks Weekly (Sep 5th): Tencent, China Hongqiao, Hang Seng Bank

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
449 Views
Share
bullish•WuXi XDC Cayman
•04 Sep 2025 08:30

WuXi XDC Cayman (2268 HK) Placement: Capex to Accelerate Growth Momentum

WuXi XDC is placing 22M shares and issuing 24M shares to its controlling shareholder Wuxi Biologics at HK$58.85 per share to raise $348M to fund...

Logo
455 Views
Share
•01 Sep 2025 19:43

Simcere Pharma Placement - First Primary Raising, past Deals Have Been Mixed

Simcere Pharmaceutical Group (2096 HK) is looking to raise around US$200m via a top-up placement. In this note, we talk about the deal dynamics.

Logo
553 Views
Share
bullish•Quantitative Analysis
•01 Sep 2025 10:50

Hong Kong Connect Flows (August): $18bn Inflows

We estimate inflows into HK via southbound trade were $18bn in August, at four month high. We highlight inflows for Alibaba, Tencent, Meituan, and...

Logo
331 Views
Share
bullish•Cross Asset Strategy
•01 Sep 2025 03:08

HONG KONG ALPHA PORTFOLIO (August 2025)

Hong Kong Alpha portfolio gained 11.34% in October outperforming its benchmark and HK indexes.  The portfolio's Sharpe ratio increased to 2.91 and...

Logo
460 Views
Share
x